Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function
- PMID: 10573082
- DOI: 10.1097/00007890-199911150-00029
Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function
Abstract
Background: There have been conflicting reports of the influence of exogenous mammalian interleukin (IL)-10 on immune reactivity. These findings may reflect the pleiotropic effects of IL-10 on the functions of antigen-presenting cells and immune effector cells. The purpose of this study was to extend observations of the influence of the cytokine on organ allograft survival and to investigate its effects on the function of accessory and immune effector cells in a mouse cardiac transplant model.
Methods: C3H (H2k) recipients of heterotopic vascularized B10 (H-2b) heart allografts were treated with recombinant (r) mouse IL-10 over a wide range of doses (0.2-200 microg/day), either before the transplant (days -3, -2, -1), peri-operatively (days -1, 0, 1), or after the transplant (days 0-6). Anti-donor cytotoxic T lymphocyte activity of host spleen and graft-infiltrating cells, and circulating complement-dependent cytotoxic antibody titers were determined by isotope release assays. Mixed leukocyte reactions were used to determine the influence of IL-10 on the function of antigen-presenting cells and allogeneic responder T cells.
Results: Recipient pre-transplant administration of IL-10 (days -3, -2, -1) prolonged graft survival at all doses tested. Donor pretreatment with IL-10 (25 microg/day; days -3, -2, -1) was also effective, but less. A pre-transplant or perioperative course of IL-10, however, did not significantly affect the immunosuppressive action of tacrolimus given on days 0-6. If given only after the transplant, IL-10 either had no effect on graft survival or (at high dosage) accelerated rejection and prevented the immunosuppressive effect of cyclosporine. Pretransplant treatment of graft recipients with IL-10 reduced splenic anti-donor cytotoxic T lymphocyte activity and the incidence of graft-infiltrating CD8+ cells. There was no significant effect on circulating alloantibody titers. MLR assays revealed that preincubation of responder cells, but not stimulator spleen cells with IL-10, inhibited T cell proliferation, whereas addition of IL-10 after the start of culture modestly enhanced proliferation. Preincubation of purified T responders with IL-10 showed no inhibitory effect.
Conclusion: The modest and opposing effects of exogenous IL-10 on organ allograft survival are dependent on timing and dosage. Recipient pretreatment prolongs graft survival. This finding, together with the MLR results, suggest that IL-10 inhibits the function of host immune accessory cells and that the direct pathway of alloantigen presentation may be less susceptible to inhibition by IL-10.
Similar articles
-
Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.Transplantation. 1999 Sep 27;68(6):747-57. doi: 10.1097/00007890-199909270-00006. Transplantation. 1999. PMID: 10515374 Free PMC article.
-
Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients.Transplantation. 1998 Dec 27;66(12):1587-96. doi: 10.1097/00007890-199812270-00004. Transplantation. 1998. PMID: 9884244
-
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.Transplantation. 1997 Dec 27;64(12):1808-15. doi: 10.1097/00007890-199712270-00031. Transplantation. 1997. PMID: 9422424
-
Pretreatment of donor stimulator cells by 16,16 dimethyl prostaglandin E2 influences the recipient immune response.Surgery. 1998 Feb;123(2):171-80. Surgery. 1998. PMID: 9481403 Review.
-
Toward more selective therapies to block undesired immune responses.Kidney Int. 1989 Apr;35(4):1026-33. doi: 10.1038/ki.1989.86. Kidney Int. 1989. PMID: 2651766 Review.
Cited by
-
Prolongation of liver allograft survival by dendritic cells modified with NF-kappaB decoy oligodeoxynucleotides.World J Gastroenterol. 2004 Aug 15;10(16):2361-8. doi: 10.3748/wjg.v10.i16.2361. World J Gastroenterol. 2004. PMID: 15285020 Free PMC article.
-
Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection.Immunology. 2000 Oct;101(2):233-41. doi: 10.1046/j.1365-2567.2000.00096.x. Immunology. 2000. PMID: 11012777 Free PMC article.
-
CD14highCD16+ monocytes are the main producers of Interleukin-10 following clinical heart transplantation.Front Immunol. 2023 Oct 23;14:1257526. doi: 10.3389/fimmu.2023.1257526. eCollection 2023. Front Immunol. 2023. PMID: 37936714 Free PMC article.
-
Effect of β-Nicotinamide Adenine Dinucleotide on Acute Allograft Rejection After Rat Lung Transplantation.Transplant Direct. 2023 Aug 9;9(9):e1516. doi: 10.1097/TXD.0000000000001516. eCollection 2023 Sep. Transplant Direct. 2023. PMID: 37575952 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials